Senores Pharmaceuticals Ltd reported Q2 FY27 revenue of ₹192.3 crore, up 24.9% year on year, and net profit of ₹36.6 crore.
- Q2 EBITDA margin rose 290 bps to 30.0%.
- H1 FY27 revenue grew 30.0% to ₹372.5 crore; net profit increased 32.6% to ₹67.0 crore, with EBITDA margin up 530 bps to 29.9%.
- The company expects H2 improvement from anticipated launches, with future contributions from Zoraya and Amerisyn.